REFERENCES
- Garbe C, Peris K, Hauschild A, Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012. Eur J Cancer. 2012;48(15):2375–2390.
- Kirkwood JM, Jukic DM, Averbook BJ, Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009;36(5):419–431.
- Kirkwood JM, Bender C, Agarwala S, Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20:3703–3718.
- Kirkwood JM, Ibrahim JG, Sondak VK, High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444–2458.
- Shah NC, Gerstle JT, Stuart M, Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the hospital for sick children experience. J Pediatr Hematol Oncol. 2006;28:496–500.
- Navid F, Furman WL, Fleming M, The feasibility of adjuvant interferon α-2b in children with high-risk melanoma. Cancer. 2005;103:780–787.
- Nashan D, Reuter K, Mohr P, Understanding and managing interferon-α-related fatigue in patients with melanoma. Melanoma Res. 2012;22(6):415–423.
- Galvão-de Almeida A, Guindalini C, Batista-Neves S, Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry. 2010;32(4):401–405.